MASALA, ERICO
MASALA, ERICO
Medicina Sperimentale e Clinica
Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?
2016 Kosmider, Olivier; Passet, Marie; Santini, Valeria; Platzbecker, Uwe; Andrieu, Valérie; Zini, Gina; Beyne-Rauzy, Odile; Guerci, Agnès; Masala, Erico; Balleari, Enrico; Bulycheva, Ekaterina; Dreyfus, François; Fenaux, Pierre; Fontenay, Michaela; Park, Sophie
Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study
2018 Basiorka A.A.; McGraw K.L.; Abbas-Aghababazadeh F.; McLemore A.F.; Vincelette N.D.; Ward G.A.; Eksioglu E.A.; Sallman D.A.; Ali N.A.; Padron E.; Pinilla-Ibarz J.; Komrokji R.; Masala E.; Santini V.; Kosmider O.; Fontenay M.; Fenaux P.; Sokol L.; Wei S.; Fridley B.; List A.F.
Combined effects of melatonin and all-trans retinoic acid and somatostatin on breast cancer cell proliferation and death: molecular basis for the anticancer effect of these molecules.
2012 Margheri, M.; Pacini, N.; Tani, A.; Nosi, D.; Squecco, R.; Dama, A.; Masala, E.; Francini, F.; Zecchi, S.; Formigli, L. .
Distinct signal transduction abnormalities and erythropoietin response in bone marrow hematopoietic cell subpopulations of myelodysplastic syndrome patients.
2012 Spinelli E; Caporale R; Buchi F; Masala E; Gozzini A; Sanna A; Sassolini F; Valencia A; Bosi A; Santini V.
Distinct signal transduction abnormalities and erythropoietin response in bone marrow hematopoietic cell subpopulations of myelodysplastic syndrome patients.
2012 Spinelli E;Caporale R;Buchi F;Masala E;Gozzini A;Sanna A;Sassolini F;Valencia A;Bosi A;Santini V
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine
2014 VALENCIA MARTINEZ, ANA BELEN; Masala, Erico; Rossi, A.; Martino, A.; Sanna, A.; Buchi, Francesca; Canzian, F.; Cilloni, D.; Gaidano, V.; Voso, M. T.; Kosmider, O.; Fontenay, M.; Gozzini, A.; Bosi, Alberto; Santini, Valeria
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine.
2014 Valencia A; Masala E; Rossi A; Martino A; Sanna A; Buchi F; Canzian F; Cilloni D; Gaidano V; Voso MT; Kosmider O; Fontenay M; Gozzini A; Bosi A; Santini V.
Hypermethylation of Wnt antagonist gene promoters and activation of Wnt pathway in myelodysplastic marrow cells.
2012 E. Masala; A. Valencia; F. Buchi; D. Nosi; E. Spinelli; A. Gozzini; F. Sassolini; A. Sanna; S. Zecchi; A. Bosi; V. Santini
Mutated ASXL1 and number of somatic mutations as possible indicators of progression to chronic myelomonocytic leukemia of myelodysplastic syndromes with single or multilineage dysplasia
2017 Valencia-Martinez, Ana; Sanna, Alessandro; Masala, Erico; Contini, Elisa; Brogi, Alice; Gozzini, Antonella; Santini, Valeria
Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes
2021 Ward G.A.; McGraw K.L.; Abbas-Aghababazadeh F.; Meyer B.S.; McLemore A.F.; Vincelette N.D.; Lam N.B.; Aldrich A.L.; Al Ali N.H.; Padron E.; Pinilla-Ibarz J.; Masala E.; Santini V.; Kosmider O.; Fontenay M.; Fenaux P.; Johnson J.; Fridley B.L.; List A.F.
Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes
2017 Cluzeau, Thomas; McGraw, Kathy L; Irvine, Brittany; Masala, Erico; Ades, Lionel; Basiorka, Ashley A; Maciejewski, Jaroslaw; Auberger, Patrick; Wei, Sheng; Fenaux, Pierre; Santini, Valeria; List, Alan
Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine.
2012 Buchi, Francesca; Spinelli, E; Masala, E; Gozzini, A; Sanna, A; Bosi, Alberto; Ferrari, G; Santini, Valeria
Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine.
2012 Buchi F; Spinelli E; Masala E; Gozzini A; Sanna A; Bosi A; Ferrari G; Santini V.
Redistribution of H3K27me3 and acetylated histone H4 upon exposure to azacitidine and decitabine results in de-repression of the AML1/ETO target gene IL3.
2014 Buchi F; Masala E; Rossi A; Valencia A; Spinelli E; Sanna A; Gozzini A; Santini V.
SELEZIONE MEDIANTE IPOSSIA PROFONDA DI CELLULE PROGENITRICI RIPOPOLANTI MEDIANTE COLTURE PRIMARIE DI CELLULE MIDOLLARI DI MDS
2013 Erico Masala
Serum Inflamma-miR Signature: A Biomarker of Myelodysplastic Syndrome?
2020 Mariani M.; Mattiucci D.; Rossi E.; Mari V.; Masala E.; Giuliani A.; Santini V.; Olivieri F.; Marinelli Busilacchi E.; Mancini S.; Olivieri A.; Poloni A.
Severe hypoxia selects hematopoietic progenitors with stem cell potential from primary Myelodysplastic syndrome bone marrow cell cultures.
2018 Masala E, Valencia-Martinez A, Pillozzi S, Rondelli T, Brogi A, Sanna A, Gozzini A, Arcangeli A, Dello Sbarba P, Santini V
Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia
2015 Meldi, Kristen; Qin, Tingting; Buchi, Francesca; Droin, Nathalie; Sotzen, Jason; Micol, Jean-Baptiste; Selimoglu-Buet, Dorothée; Masala, Erico; Allione, Bernardino; Gioia, Daniela; Poloni, Antonella; Lunghi, Monia; Solary, Eric; Abdel-Wahab, Omar; Santini, Valeria; Figueroa, Maria E.
The Leukemic Stem Cell Niche: Adaptation to “Hypoxia” versus Oncogene Addiction
2017 Cheloni, G; Poteti, M; Bono, S; Masala, E; Mazure, N; Rovida, E; Lulli, M; Dello Sbarba, P
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes? | 2016 | Kosmider, Olivier; Passet, Marie; Santini, Valeria; Platzbecker, Uwe; Andrieu, Valérie; Zini, Gina; Beyne-Rauzy, Odile; Guerci, Agnès; Masala, Erico; Balleari, Enrico; Bulycheva, Ekaterina; Dreyfus, François; Fenaux, Pierre; Fontenay, Michaela; Park, Sophie | |
| Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study | 2018 | Basiorka A.A.; McGraw K.L.; Abbas-Aghababazadeh F.; McLemore A.F.; Vincelette N.D.; Ward G.A.; Eksioglu E.A.; Sallman D.A.; Ali N.A.; Padron E.; Pinilla-Ibarz J.; Komrokji R.; Masala E.; Santini V.; Kosmider O.; Fontenay M.; Fenaux P.; Sokol L.; Wei S.; Fridley B.; List A.F. | |
| Combined effects of melatonin and all-trans retinoic acid and somatostatin on breast cancer cell proliferation and death: molecular basis for the anticancer effect of these molecules. | 2012 | Margheri, M.; Pacini, N.; Tani, A.; Nosi, D.; Squecco, R.; Dama, A.; Masala, E.; Francini, F.; Zecchi, S.; Formigli, L. . | |
| Distinct signal transduction abnormalities and erythropoietin response in bone marrow hematopoietic cell subpopulations of myelodysplastic syndrome patients. | 2012 | Spinelli E; Caporale R; Buchi F; Masala E; Gozzini A; Sanna A; Sassolini F; Valencia A; Bosi A; Santini V. | |
| Distinct signal transduction abnormalities and erythropoietin response in bone marrow hematopoietic cell subpopulations of myelodysplastic syndrome patients. | 2012 | Spinelli E;Caporale R;Buchi F;Masala E;Gozzini A;Sanna A;Sassolini F;Valencia A;Bosi A;Santini V | |
| Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine | 2014 | VALENCIA MARTINEZ, ANA BELEN; Masala, Erico; Rossi, A.; Martino, A.; Sanna, A.; Buchi, Francesca; Canzian, F.; Cilloni, D.; Gaidano, V.; Voso, M. T.; Kosmider, O.; Fontenay, M.; Gozzini, A.; Bosi, Alberto; Santini, Valeria | |
| Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine. | 2014 | Valencia A; Masala E; Rossi A; Martino A; Sanna A; Buchi F; Canzian F; Cilloni D; Gaidano V; Voso MT; Kosmider O; Fontenay M; Gozzini A; Bosi A; Santini V. | |
| Hypermethylation of Wnt antagonist gene promoters and activation of Wnt pathway in myelodysplastic marrow cells. | 2012 | E. Masala; A. Valencia; F. Buchi; D. Nosi; E. Spinelli; A. Gozzini; F. Sassolini; A. Sanna; S. Zecchi; A. Bosi; V. Santini | |
| Mutated ASXL1 and number of somatic mutations as possible indicators of progression to chronic myelomonocytic leukemia of myelodysplastic syndromes with single or multilineage dysplasia | 2017 | Valencia-Martinez, Ana; Sanna, Alessandro; Masala, Erico; Contini, Elisa; Brogi, Alice; Gozzini, Antonella; Santini, Valeria | |
| Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes | 2021 | Ward G.A.; McGraw K.L.; Abbas-Aghababazadeh F.; Meyer B.S.; McLemore A.F.; Vincelette N.D.; Lam N.B.; Aldrich A.L.; Al Ali N.H.; Padron E.; Pinilla-Ibarz J.; Masala E.; Santini V.; Kosmider O.; Fontenay M.; Fenaux P.; Johnson J.; Fridley B.L.; List A.F. | |
| Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes | 2017 | Cluzeau, Thomas; McGraw, Kathy L; Irvine, Brittany; Masala, Erico; Ades, Lionel; Basiorka, Ashley A; Maciejewski, Jaroslaw; Auberger, Patrick; Wei, Sheng; Fenaux, Pierre; Santini, Valeria; List, Alan | |
| Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine. | 2012 | Buchi, Francesca; Spinelli, E; Masala, E; Gozzini, A; Sanna, A; Bosi, Alberto; Ferrari, G; Santini, Valeria | |
| Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine. | 2012 | Buchi F; Spinelli E; Masala E; Gozzini A; Sanna A; Bosi A; Ferrari G; Santini V. | |
| Redistribution of H3K27me3 and acetylated histone H4 upon exposure to azacitidine and decitabine results in de-repression of the AML1/ETO target gene IL3. | 2014 | Buchi F; Masala E; Rossi A; Valencia A; Spinelli E; Sanna A; Gozzini A; Santini V. | |
| SELEZIONE MEDIANTE IPOSSIA PROFONDA DI CELLULE PROGENITRICI RIPOPOLANTI MEDIANTE COLTURE PRIMARIE DI CELLULE MIDOLLARI DI MDS | 2013 | Erico Masala | |
| Serum Inflamma-miR Signature: A Biomarker of Myelodysplastic Syndrome? | 2020 | Mariani M.; Mattiucci D.; Rossi E.; Mari V.; Masala E.; Giuliani A.; Santini V.; Olivieri F.; Marinelli Busilacchi E.; Mancini S.; Olivieri A.; Poloni A. | |
| Severe hypoxia selects hematopoietic progenitors with stem cell potential from primary Myelodysplastic syndrome bone marrow cell cultures. | 2018 | Masala E, Valencia-Martinez A, Pillozzi S, Rondelli T, Brogi A, Sanna A, Gozzini A, Arcangeli A, Dello Sbarba P, Santini V | |
| Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia | 2015 | Meldi, Kristen; Qin, Tingting; Buchi, Francesca; Droin, Nathalie; Sotzen, Jason; Micol, Jean-Baptiste; Selimoglu-Buet, Dorothée; Masala, Erico; Allione, Bernardino; Gioia, Daniela; Poloni, Antonella; Lunghi, Monia; Solary, Eric; Abdel-Wahab, Omar; Santini, Valeria; Figueroa, Maria E. | |
| The Leukemic Stem Cell Niche: Adaptation to “Hypoxia” versus Oncogene Addiction | 2017 | Cheloni, G; Poteti, M; Bono, S; Masala, E; Mazure, N; Rovida, E; Lulli, M; Dello Sbarba, P |